ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01831089
Recruitment Status : Completed
First Posted : April 15, 2013
Last Update Posted : July 27, 2016
Sponsor:
Information provided by (Responsible Party):
PharmaMar

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : July 2016
  Actual Study Completion Date : July 2016

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 September 26, 2017